AP
SGMT icon

Antipodes Partners’s Sagimet Biosciences SGMT Stock Holding History

Antipodes Partners’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,176
Closed -$18.8K – 149
2025
Q4 		$18.8K Hold
3,176
– – ﹤0.01% 125
2025
Q3 		$21.8K Sell
3,176
-2,236
-41% -$18.1K ﹤0.01% 110
2025
Q2 		$41.2K Buy
+5,412
New +$22.8K ﹤0.01% 90

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Antipodes Partners's SGMT Position: Q1 2026 in Review

Antipodes Partners sold out of Sagimet Biosciences (SGMT) in Q1 2026, closing a stake of 3,176 shares — an estimated $18.8K sold.

Antipodes Partners first reported a position in SGMT in Q2 2025 and held it in 3 quarters. The position peaked at $41.2K in Q2 2025. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • Antipodes Partners reported no remaining Sagimet Biosciences position as of Q1 2026 after selling out during the quarter.
  • Antipodes Partners sold 3,176 Sagimet Biosciences shares in Q1 2026, an estimated $18.8K.
  • Antipodes Partners first reported a position in Sagimet Biosciences in Q2 2025 and held it in 3 quarters.
  • Antipodes Partners's Sagimet Biosciences position peaked at $41.2K in Q2 2025.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on Antipodes Partners's 13F filing for Q1 2026, filed 5 May 2026.